FDA Grants Orphan Drug Designation to Biodel Inc.l's Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population

DANBURY, Conn., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that the FDA has granted orphan drug designation for Biodel's 'glucagon' for the prevention of hypoglycemia in the congenital hyperinsulinism (CHI) population.

Back to news